Revance Therapeutics Inc. (NASDAQ:RVNC) shares rose 2.4% during trading on Tuesday . The company traded as high as $14.23 and last traded at $14.00, with a volume of 54,227 shares changing hands. The stock had previously closed at $13.67.

RVNC has been the topic of a number of research reports. Guggenheim reissued a “buy” rating and set a $55.00 target price on shares of Revance Therapeutics in a research report on Tuesday, June 14th. Brean Capital reissued a “buy” rating on shares of Revance Therapeutics in a research report on Saturday, June 4th. SunTrust Banks Inc. cut their target price on shares of Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating on the stock in a research report on Tuesday, June 14th. Zacks Investment Research raised shares of Revance Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Wednesday, July 13th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $35.00 target price (down previously from $54.00) on shares of Revance Therapeutics in a research report on Tuesday, June 14th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Revance Therapeutics presently has a consensus rating of “Buy” and an average target price of $39.60.

The stock’s market cap is $402.48 million. The stock has a 50-day moving average price of $14.14 and a 200 day moving average price of $16.62.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.02. The firm had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.06 million. The business’s revenue was up .0% on a year-over-year basis. On average, analysts forecast that Revance Therapeutics Inc. will post ($3.53) earnings per share for the current year.

An institutional investor recently bought a new position in Revance Therapeutics stock. Ameriprise Financial Inc. bought a new position in shares of Revance Therapeutics Inc. (NASDAQ:RVNC) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 41,957 shares of the biopharmaceutical company’s stock, valued at approximately $1,433,000. Ameriprise Financial Inc. owned approximately 0.15% of Revance Therapeutics as of its most recent SEC filing.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.